New patent Apr 30/21 MD&A - In addition to the two patents granted in 2018, we have applied for a continuation patent on our US cannabinoid patent and have been issued the patent in Canada for “Methods of Treating Inflammatory Disorders and Global Inflammation with Compositions Comprising Phospholipid Nanoparticle Encapsulations of NSAIDs”. This new patent opens the door to discussions with pharmaceutical companies on how we may partner to develop and commercialize a line of NSAID-related products.
https://patents.google.com/patent/CA3050535A1/en
Novel process and products thereby emplace NSAIDS within nanodelivery vehicles for various indications in mammals, including humans. This disclosure teaches phospholipid nanoparticle compositions of NSAIDs formed from phospholipids and simpler lipids in an unfired sequential process that encapsulate a high concentration of NSAIDs; yielding an increase NSAID transport across hydrophobic mucosa; increase the bioavailability of the NSAID 2-fold to 10-fold, decrease the dose of NSAIDs 2-fold to 10-fold less than an amount of NSAID needed to illicit the same therapeutic effect compared to standard NSAID pills and capsules currently sold; where the phospholipids in the nanoparticle structure reduce or eliminate pathogenic effects of NSAIDs; and enable safe, daily, long term and more efficacious NSAID therapy and treatment and prevention of inflammatory disorders and global inflammation
.....wherein the nanoparticle structure is for administration to a mammal via the sublingual mucosa, via the buccal mucosa, across ocular barriers into ocular tissues, across dermal and epidermal barriers, via an intranasal route of administration to bypass the Blood Brain Barrier.